Please upgrade your browser.
With the mythbusting powers for which she is acclaimed, Ehrenreich exposes the downside of Americas penchant for positive thinking: On a personal level, it leads to self-blame and a morbid preoccupation with stamping out negative thoughts. On a national level, its brought us an era of irrational optimism resulting in disaster. This is Ehrenreich at her provocative bestpoking holes in conventional wisdom and faux science, and ending with a call for existential clarity and courage.
Thanks to Mike Lawing for preparing this (PDF) summary from the Eighth International Kidney Cancer Symposium, held in Chicago, in the fall of 2009.
Kidney Cancer Chat has a new home on the Internet. Please visit the site and bookmark it. This replaces the chat applet that was installed on the Kidney Cancer Association's site (that is no longer functional, due to technical issues). This is an unmoderated chat, not affiliated with the Association. All are welcome. Keyword: "kidneycancer."
Pazopanib may double time to disease progression, study finds.
CLINICAL trials of Bionomics' lead anti-cancer compound have opened for enrolment in the US.
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a commercialization agreement with Novartis under which Prometheus acquired exclusive rights to distribute, promote and sell PROLEUKINÂ® (aldesleukin) in the United States. Proleukin is a recombinant human interleukin-2 for treatment in adults with metastatic melanoma and metastatic kidney cancer.
In this Talkshoe.com audio podcast, Maria Coleman Filorimo and author Tracy Gray talk with Kidney Cancer Association CEO Bill Bro about their experiences in living with a child who has kidney cancer. It's a half-hour of of inspiring and frank conversation, filled with joy, tears, and love, as two moms detail their experiences in raising a girl and boy with renal cancer. Clicking the hyperlink will launch your media player.
New research by health economists at the University of York has raised concerns over any move to broaden the range of costs and economic benefits considered in the analysis of new NHS treatments.
Patient: "Forty-six thousand Canadians are diagnosed with kidney cancer a year and 16,000 will die. I know kidney cancer isn't as high profile as prostate or breast cancer, but we need access to life improving drugs."
|Powered by NeonCRM|